Printer Friendly

ENROLLMENT COMPLETED IN ALPHA 1 BIOMEDICALS' PHASE III CLINICAL TRIAL

 BETHESDA, Md., April 27 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM) today announced the entry of the final patient in its Phase III clinical trial for chronic hepatitis B. The last patient will be treated for six months and then followed for six months. The trial will be unblinded at the end of April 1994.
 The physicians conducting the Phase III trial and their respective affiliations include the principal investigator, Dr. Milton G. Mutchnick of Wayne State University, Detroit; Dr. Karen L. Lindsay, USC, Los Angeles; and Dr. Eugene R. Schiff, The University of Miami, Miami.
 Vincent F. Simmon, president and CEO of Alpha 1 stated, "We are delighted that enrollment in this important trial is now completed. To date, the trial is meeting our expectations and we are anxiously awaiting the unblinding of the data. Our goal will be to submit a New Drug Application (NDA) to the FDA by the end of 1994."
 Alpha 1 Biomedicals, Inc. is engaged in the development of pharmaceutical products for the treatment of chronic viral diseases, immune disorders and cancer. The company's lead drug, Thymosin alpha 1, is currently in U.S. clinical trials for the treatment of chronic hepatitis B, chronic hepatitis C and AIDS.
 -0- 4/27/93
 /CONTACT: Vincent F. Simmon, Ph.D., president and CEO of Alpha 1 Biomedicals, 301-564-4400; or Anita Monteith-Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1 Biomedicals/
 (ALBM)


CO: Alpha 1 Biomedicals, Inc. ST: Maryland IN: MTC SU:

PS-SH -- NY022 -- 1154 04/27/93 08:55 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 27, 1993
Words:254
Previous Article:HERTZ EXPANDS IN MIDDLE EAST; OPENS IN QATAR, ARAB EMIRATES AND BAHRAIN
Next Article:TI AND HYUNDAI SIGN CROSS-LICENSE AGREEMENT
Topics:


Related Articles
U.S. TESTS OF POTENTIAL AIDS VACCINE CONFIRM EARLIER U.K. TESTS
ALPHA 1 BIOMEDICALS INC. ANNOUNCES MANUFACTURING EXPANSION
UPDATE ON HGP-30 AIDS VACCINE PRESENTED AT BERLIN AIDS CONFERENCE
THYMOSIN ALPHA 1 COMBINATION STUDY SUGGESTS CD4+ RESPONSE
Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters